Clinical Trial Update: Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer [Phase 2]

View source ↗

Summary

This update reports the results of a Phase 2 trial of erlotinib as a single agent in chemotherapy-naive androgen-independent (castration-resistant) prostate can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Oncology Specialists, S.C. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-10-17